Abstract #0805

Dynamic contrast enhanced MRI detects pancreatic cancer responses to stroma-directed therapy

Jianbo Cao¹, Stephen Pickup¹, Cynthia Clendenin^2,3, Barbara Blouw⁴, David Kang⁴, Peter O'Dwyer^2,3, and Rong Zhou^1,3

¹Radiology, University of Pennsylvania, Philadelphia, PA, United States, ²Pancreatic Cancer Research Center, University of Pennsylvania, Philadelphia, PA, United States, ³Abramson Cancer Center, University of Pennsylvania, philadelphia, PA, United States, ⁴Halozyme Therapeutics, San Diego, CA, United States

Stroma-targeted treatments of pancreatic ductal carcinoma (PDA) has been widely investigated, but there is no imaging method that has been validated for early and noninvasive monitoring of the tumor responses to stroma-directed treatments. Here we treated murine PDA models with an investigational drug, PEGPH20, which removes a stroma component called hyaluronan. We examined whether DCE-MRI can characterize the treat responses. Our results demonstrated that this technique can detect stromal changes as early as 24 h post treatment, and the MRI results are corroborated with HA-staining. Further validation and potential clinical translation are warranted.

This abstract and the presentation materials are available to members only; a login is required.

Join Here